China Biologic Products Inc (CBPO) : Harvard Management Co Inc reduced its stake in China Biologic Products Inc by 19.88% during the most recent quarter end. The investment management company now holds a total of 40,300 shares of China Biologic Products Inc which is valued at $5,063,292 after selling 10,000 shares in China Biologic Products Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.China Biologic Products Inc makes up approximately 1.05% of Harvard Management Co Inc’s portfolio.
Other Hedge Funds, Including , Geode Capital Management boosted its stake in CBPO in the latest quarter, The investment management firm added 237 additional shares and now holds a total of 10,749 shares of China Biologic Products Inc which is valued at $1,350,504. Lmr Partners Llp sold out all of its stake in CBPO during the most recent quarter. The investment firm sold 10,970 shares of CBPO which is valued $1,309,599. Ariose Capital Management Ltd sold out all of its stake in CBPO during the most recent quarter. The investment firm sold 88,655 shares of CBPO which is valued $10,583,634. Capital Fund Management S.a. added CBPO to its portfolio by purchasing 2,522 company shares during the most recent quarter which is valued at $296,839. China Biologic Products Inc makes up approx 0.01% of Capital Fund Management S.a.’s portfolio.Copper Rock Capital Partners boosted its stake in CBPO in the latest quarter, The investment management firm added 10,560 additional shares and now holds a total of 20,960 shares of China Biologic Products Inc which is valued at $2,313,984. China Biologic Products Inc makes up approx 0.17% of Copper Rock Capital Partners’s portfolio.
China Biologic Products Inc opened for trading at $112.2 and hit $113.5 on the upside on Monday, eventually ending the session at $112.08, with a gain of 0.05% or 0.06 points. The heightened volatility saw the trading volume jump to 2,68,765 shares. Company has a market cap of $3,014 M.
On the company’s financial health, China Biologic Products Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.18. The company had revenue of $91.42 million for the quarter, compared to analysts expectations of $87.58 million. The company’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS.
China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).